Skip to content

Professor Dalgleish is a specialist in identifying the properties of existing treatments and repurposing them for new clinical applications.

He is known for his work on enhancing the therapeutic properties of thalidomide to develop two new drugs, Lenalidomide and Pomalidomide, which are now both used for the treatment of multiple myeloma and lymphoma. For this pioneering work, Professor Dalgleish was awarded the Lederberg Prize by Celgene.

In recent work, Professor Dalgleish has demonstrated that a vaccine originally developed for TB (IMM-101) greatly enhances the immune response to cancers, either when given alone or in combination with chemotherapy or other immunotherapies. Unlike most other treatment, this method has no systemic toxicity.

Professor Dalgleish has reported that patients who do not respond to immunotherapy have high levels of inflammatory proteins. Combining anti-inflammatory agents with immunotherapy should enhance response rates. This may explain why Naltrexone, which he has reported as inhibiting the TLR-9 inflammatory marker, appears to benefit cancer patients.

Together with Dr Wai Liu, he has been exploring the potential of cannabinoid derivatives to treat cancer. They appear to enhance the beneficial effects of radiotherapy and chemotherapy without any additional toxicity.

Professor Dalgleish has been made a Visiting Professor at the Earle Chiles Research Institute, Portland, U.S.A. (Director: Bernard Fox).

Presentations and publications


Find a profileSearch by A-Z